![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Z Terashita, Y Imura, M Takatani, S Tsushima and K Nishikawa
2-[N-acetyl-N-(2-methoxy-3-octadecylcarbamoyloxypropoxycarbonyl) aminomethyl]-1-ethylpyridinium chloride (CV-6209) inhibited aggregation of rabbit and human platelets induced by platelet activating factor (PAF) with the IC50 values of 7.5 X 10(-8) and 1.7 X 10(-7) M, respectively, and had little effects on the aggregation induced by arachidonic acid, ADP and collagen. The inhibitory effect of CV-6209 on the PAF-induced rabbit platelet aggregation was 104, 9, 8 and 3 times more potent than the PAF antagonists CV-3988, ONO-6240, Ginkgolide B and etizolam, respectively. CV-6209 inhibited [3H]serotonin release from rabbit platelets stimulated with PAF (3 X 10(-8) M) with a similar potency as the inhibition on the platelet aggregation. CV-6209 inhibited PAF (0.3 microgram/kg i.v.)-induced hypotension in rats (ED50, 0.009 mg/kg i.v.) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol. CV-6209 (1 mg/kg) inhibited slightly the acetylcholine-induced hypotension. In rats, post-treatment with CV-6209 reversed the PAF (1 microgram/kg i.v.)-induced hypotension rapidly (ED50, 0.0046 mg/kg i.v.); CV-6209 was 74, 20, 185 and over 2100 times more potent than CV-3988, ONO-6240, Ginkgolide B and etizolam, respectively. Thus, the relative potency of the anti-PAF action of PAF analog (CV-6209, CV-3988 and ONO-6240) differed little between the inhibition of PAF-induced platelet aggregation and the reversal of PAF-induced hypotension, but that of nonPAF analogs (Ginkgolide B and etizolam) differed greatly with these assay systems, when standardized with CV-6209.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  T. Shimada, T. Hirose, I. Matsumoto, and T. Aikawa Platelet-activating factor acts on cortisol secretion by perfused guinea-pig adrenals via calcium-/phospholipid-dependent mechanisms J. Endocrinol., February 1, 2005; 184(2): 381 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bonin, S. D. Ryan, L. Migahed, F. Mo, J. Lallier, D. J. Franks, H. Arai, and S. A. L. Bennett Anti-apoptotic Actions of the Platelet-activating Factor Acetylhydrolase I {alpha}2 Catalytic Subunit J. Biol. Chem., December 10, 2004; 279(50): 52425 - 52436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Elovitz, Z. Wang, E. K. Chien, D. F. Rychlik, and M. Phillippe A New Model for Inflammation-Induced Preterm Birth: The Role of Platelet-Activating Factor and Toll-Like Receptor-4 Am. J. Pathol., November 1, 2003; 163(5): 2103 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pedotti, J. J. DeVoss, S. Youssef, D. Mitchell, J. Wedemeyer, R. Madanat, H. Garren, P. Fontoura, M. Tsai, S. J. Galli, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination PNAS, February 18, 2003; 100(4): 1867 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kato, H. Kimura, Y. Motegi, A. Tachibana, H. Minakami, A. Morikawa, and H. Kita Platelet-Activating Factor Activates Two Distinct Effector Pathways in Human Eosinophils J. Immunol., November 1, 2002; 169(9): 5252 - 5259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Biancone, V. Cantaluppi, M. Boccellino, B. Bussolati, L. Del Sorbo, P. G. Conaldi, A. Albini, A. Toniolo, and G. Camussi Motility Induced by Human Immunodeficiency Virus-1 Tat on Kaposi’s Sarcoma Cells Requires Platelet-Activating Factor Synthesis Am. J. Pathol., November 1, 1999; 155(5): 1731 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhu, N. M. Munoz, K. P. Kim, H. Sano, W. Cho, and A. R. Leff Cytosolic Phospholipase A2 Activation Is Essential for {beta}1 and {beta}2 Integrin-Dependent Adhesion of Human Eosinophils J. Immunol., September 15, 1999; 163(6): 3423 - 3429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Bartemes, S. McKinney, G. J. Gleich, and H. Kita Endogenous Platelet-Activating Factor Is Critically Involved in Effector Functions of Eosinophils Stimulated with IL-5 or IgG J. Immunol., March 1, 1999; 162(5): 2982 - 2989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Gupta, M. Prasad, J. Kalra, and K. Prasad Platelet-Activating-Factor-Induced Changes in Cardiovascular Function and Oxyradical Status of Myocardium in Presence of the PAF Antagonist CV-6209 Angiology, January 1, 1994; 45(1): 25 - 36. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
